Blood typing has become a routine test item of clinical blood transfusion department and clinical laboratory, which includes ABO blood group, Rh blood group, and cross-matching of blood test.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL, Inc. (Nasdaq: GRAL), today announced they have signed a binding Letter of Intent for a strategic collaboration to bring GRAIL's GalleriⓇ multi-cancer early detection (MCED) test to key Asian markets. SCT and SEC have also agreed to invest $110 million into GRAIL, a healthcare company whose mission is to detect cancer early when it can be cured, at a price of $70.05 per share of common stock.

Thermo Fisher Scientific, the world leader in serving science, has introduced the Applied Biosystems™ SwiftArrayStudio™ Microarray Analyzer, designed for fast and scalable sample analysis. In conjunction with two new arrays – the Applied Biosystems Axiom™ PharmacoPro™ Array and the Applied Biosystems Axiom PangenomePro Array – the analyzer combines four key genotyping processes into a single, integrated device, enabling researchers to cover the widest range of populations for Genome-Wide Association Studies (GWAS) and accelerate breakthrough discoveries in pharmacogenomics that will help drive the future of precision medicine forward.

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2025.

OSR Holdings, Inc. (NASDAQ: OSRH) today announced that it has executed a definitive agreement to acquire Woori IO Co., Ltd. ("WORIO"), a pioneer in noninvasive glucose monitoring (NIGM), via a comprehensive share exchange. The acquisition reinforces OSRH's dedication to advancing biomedical innovation by adding a potential breakthrough technology for diabetes care, bringing truly needle-free glucose monitoring closer to patients globally and promising a safer, more convenient and accurate alternative to currently available technologies.

China leads the world in AI research publications related to the global medical device field over the past five years, according to a latest industrial white paper.

China’s National Health Commission (NHC) recently responded to a deputies’ proposal on “Lifting Restrictions on Diagnostic Testing Services in Clinics to Promote the Implementation of Tiered Healthcare”:

In terms of the domestic IVD markets of hemostasis and thrombosis, the special testing items are gradually promoted and popularized in domestic medical institutions.

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States Food and Drug Administration (FDA) has cleared its Elecsys pTau181 test, the only blood-based biomarker (BBM) test indicated as an aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting. The Elecsys pTau181 test is intended for patients ages 55 and older presenting with signs, symptoms or complaints of cognitive decline. It measures phosphorylated Tau (pTau) 181 protein in human plasma, a key biomarker for Alzheimer’s pathology, including amyloid plaque and tau aggregate pathology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

Private equity group Warburg Pincus is nearing a deal to take a large minority stake in French diagnostics group Sebia, which values the business at €5.4bn, according to people familiar with the matter.